Prevalence of transient hyperphosphatasemia among healthy infants and toddlers

Susanna Y Huh1, Henry A Feldman, Joanne E Cox

  • 1Division of Gastroenterology, Children's Hospital Boston, Boston, Massachusetts 02115, USA. susanna.huh@childrens.harvard.edu

Pediatrics
|July 22, 2009
PubMed

Insights

Transient hyperphosphatasemia (TH) is common in healthy infants and toddlers. This benign condition, characterized by high alkaline phosphatase (AP) levels, is not linked to nutritional or mineral deficiencies.

Area of Science:

  • Pediatrics
  • Biochemistry

Background:

  • Transient hyperphosphatasemia (TH) is a condition characterized by temporary elevations in serum alkaline phosphatase (AP) levels.
  • Its prevalence and clinical associations in healthy young children are not well-defined.

Purpose of the Study:

  • To determine the prevalence of TH in healthy infants and toddlers.
  • To describe the clinical characteristics associated with TH in this population.

Main Methods:

  • Secondary data analysis of 316 healthy children aged 8-24 months from a vitamin D deficiency study.
  • Serum alkaline phosphatase (AP), 25-hydroxyvitamin D, parathyroid hormone (PTH), calcium, magnesium, and phosphorus levels were measured.
  • Children categorized into normal (AP: 110-400 U/L), intermediate (AP: >400-1000 U/L), and TH (AP: >1000 U/L) groups.

Main Results:

  • Nine children (2.8%) met criteria for TH (mean AP: 2165 U/L).
  • Sixteen children (5.1%) had intermediate AP levels (mean AP: 544 U/L).
  • No significant differences in anthropometric measures, vitamin D, PTH, or mineral levels were observed between groups.

Conclusions:

  • Transient hyperphosphatasemia is a relatively common finding in healthy infants and toddlers.
  • TH is not associated with anthropometric status, vitamin D levels, or other serum minerals.
  • Recognizing TH as a benign condition is crucial to prevent unnecessary medical investigations.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Roles of Electrolytes: Calcium and Phosphate01:27

Roles of Electrolytes: Calcium and Phosphate

Calcium and phosphate are essential electrolytes in the human body, with calcium being the most abundant mineral. Around 99% of the body's calcium is stored in the skeleton and teeth, forming a crystal lattice of mineral salts in combination with phosphates. Calcium plays crucial roles in various bodily functions such as blood clotting, neurotransmitter release, muscle tone maintenance, and nervous and muscle tissue excitability.
The calcium concentration in blood plasma is primarily regulated...